RHD zygosity predicts degree of platelet response to anti-D immune globulin treatment in children with immune thrombocytopenia
Abstract
Anti-D immunoglobulin is a common front-line treatment for childhood immune thrombocytopenia (ITP) that typically results in a rapid and significant increase in platelet count. Unpredictable treatment responses and interpatient variability limit more widespread use. We hypothesized that anti-D response variability is influenced by RHD gene zygosity and erythrocyte D antigen expression. We compared RHD zygosity and quantitative D antigen expression to anti-D treatment results. Hemizygous RHD subjects demonstrated significantly higher platelet increases and peak platelet counts than homozygous RHD subjects. Future studies should investigate the mechanisms by which RHD zygosity and D antigen expression affect platelet responses to anti-D immunoglobulin. © 2013 Wiley Periodicals, Inc.
Publication Title
Pediatric Blood and Cancer
Recommended Citation
Despotovic, J., Mcgann, P., Smeltzer, M., Aygun, B., & Ware, R. (2013). RHD zygosity predicts degree of platelet response to anti-D immune globulin treatment in children with immune thrombocytopenia. Pediatric Blood and Cancer, 60 (9) https://doi.org/10.1002/pbc.24574
